ClinicaliQ Trial Snapshot
- An Open-Label Study to Evaluate the Safety, Tolerability and Pharmacodynamics of BPL-003 in Patients With Treatment Resistant Depression — Recruiting • Phase II • Mental Health / Psychiatry • NCT05660642.
- BPL-003 Trial Summary.
- Intranasal BPL-003 with psychological support tested for safety and effectiveness in treatment-resistant depression, used alone or with SSRIs.
Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
An open-label, multi-centre, Phase 2a study to evaluate the safety, tolerability, and pharmacodynamics of one and two doses of intranasal BPL-003 combined with psychological support, in patients with treatment resistant depression when administered as monotherapy or as adjunctive therapy with defined SSRIs (citalopram, escitalopram, sertraline or fluoxetine). Conditions: Treatment Resistant Depression Interventions: BPL-003 Lead Sponsor: Beckley Psytech Limited Planned Enrollment: 64 participants